Compare Stocks: CVAC, TLX, VKTX, and DNLI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
DNLI Denali Therapeutics	$24.92 -0.1%	$24.45	$12.58 ▼ $27.30	$3.98B	1.01	1.36 million shs	680,991 shs
TLX Telix Pharmaceuticals	$11.33 -8.8%	$10.96	$6.28 ▼ $12.60	$3.85B	-0.24	116,000 shs	299,619 shs
VKTX Viking Therapeutics	$33.89 -1.4%	$35.29	$22.96 ▼ $43.15	$3.95B	0.69	1.90 million shs	1.50 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.50%
DNLI Denali Therapeutics	0.00%	+2.13%	+6.40%	+33.69%	+71.74%
TLX Telix Pharmaceuticals	0.00%	-4.15%	+7.80%	+19.64%	+3.28%
VKTX Viking Therapeutics	0.00%	+2.11%	-4.24%	+9.71%	+31.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
DNLI Denali Therapeutics	$24.92 -0.1%	$24.45	$12.58 ▼ $27.30	$3.98B	1.01	1.36 million shs	680,991 shs
TLX Telix Pharmaceuticals	$11.33 -8.8%	$10.96	$6.28 ▼ $12.60	$3.85B	-0.24	116,000 shs	299,619 shs
VKTX Viking Therapeutics	$33.89 -1.4%	$35.29	$22.96 ▼ $43.15	$3.95B	0.69	1.90 million shs	1.50 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.50%
DNLI Denali Therapeutics	0.00%	+2.13%	+6.40%	+33.69%	+71.74%
TLX Telix Pharmaceuticals	0.00%	-4.15%	+7.80%	+19.64%	+3.28%
VKTX Viking Therapeutics	0.00%	+2.11%	-4.24%	+9.71%	+31.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.92	44.13% Upside
TLX Telix Pharmaceuticals	2.75	Moderate Buy	$20.40	80.05% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	185.11% Upside

Current Analyst Ratings Breakdown

Latest CVAC, TLX, VKTX, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00
8/7/2026	DNLI Denali Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $34.00
8/7/2026	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
7/30/2026	VKTX Viking Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$107.00 ➝ $114.00
7/23/2026	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $36.00
7/20/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	DNLI Denali Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
DNLI Denali Therapeutics	$330.53M	12.05	N/A	N/A	$5.22 per share	4.77
TLX Telix Pharmaceuticals	$803.79M	4.79	$0.04 per share	268.72	$1.23 per share	9.21
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	188.83	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest CVAC, TLX, VKTX, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
DNLI Denali Therapeutics	0.01	8.37	8.32
TLX Telix Pharmaceuticals	1.08	1.43	1.27
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
DNLI Denali Therapeutics	92.92%
TLX Telix Pharmaceuticals	N/A
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
DNLI Denali Therapeutics	9.70%
TLX Telix Pharmaceuticals	N/A
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
DNLI Denali Therapeutics	430	159.85 million	144.34 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

CVAC, TLX, VKTX, and DNLI Headlines

Recent News About These Companies

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 32,564 Viking Therapeutics, Inc. $VKTX

August 22 at 5:11 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research

August 20 at 6:59 AM | marketbeat.com

How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?

August 19, 2026 | finance.yahoo.com

Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX

August 19, 2026 | marketbeat.com

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

August 19, 2026 | finance.yahoo.com

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

August 17, 2026 | zacks.com

2 GLP-1 Stocks That Could Double Your Money by 2031

August 16, 2026 | fool.com

Cantor Fitzgerald Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

August 16, 2026 | theglobeandmail.com

Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX

August 15, 2026 | marketbeat.com

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

August 14, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Lowers Viking Therapeutics (NASDAQ:VKTX) Price Target to $65.00

August 13, 2026 | americanbankingnews.com

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

August 12, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price

August 11, 2026 | marketbeat.com

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

August 8, 2026 | fool.com

Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX

August 8, 2026 | marketbeat.com

Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP

August 8, 2026 | marketbeat.com

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

August 6, 2026 | fool.com

First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX

August 6, 2026 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 6, 2026 | marketbeat.com

The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why

August 4, 2026 | finance.yahoo.com

Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?

August 4, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, TLX, VKTX, and DNLI Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 08/21/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Denali Therapeutics NASDAQ:DNLI

$24.92 -0.03 (-0.12%)

As of 08/21/2026 04:00 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Telix Pharmaceuticals NASDAQ:TLX

$11.33 -1.09 (-8.78%)

As of 08/21/2026 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Viking Therapeutics NASDAQ:VKTX

$33.89 -0.47 (-1.37%)

As of 08/21/2026 04:00 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, TLX, VKTX, and DNLI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, TLX, VKTX, and DNLI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, TLX, VKTX, and DNLI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, TLX, VKTX, and DNLI Company Descriptions

CureVac NASDAQ:CVAC

Denali Therapeutics NASDAQ:DNLI

Telix Pharmaceuticals NASDAQ:TLX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, TLX, VKTX, and DNLI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, TLX, VKTX, and DNLI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, TLX, VKTX, and DNLI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, TLX, VKTX, and DNLI Company Descriptions

CureVac NASDAQ:CVAC

Denali Therapeutics NASDAQ:DNLI

Telix Pharmaceuticals NASDAQ:TLX

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools